Latest news with #RichardMalamut
Business Wire
5 days ago
- Business
- Business Wire
Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 7:35 a.m. ET (1:35 p.m. CEST). Live webcast and replay: One-on-one meetings with the management team can be scheduled with conference representatives or directly with Medincell ( About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals
Yahoo
5 days ago
- Business
- Yahoo
Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025
MONTPELLIER, France, May 28, 2025--(BUSINESS WIRE)--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 7:35 a.m. ET (1:35 p.m. CEST). Live webcast and replay: One-on-one meetings with the management team can be scheduled with conference representatives or directly with Medincell ( About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals View source version on Contacts David Heuzé Head of Corporate and Financial Communications, and / +33 (0)6 83 25 21 86 Grace Kim Chief Strategy Officer, U.S. / +1 (646) 991-4023 Nicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@ / +33 (0)1 44 71 94 94 Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@ / +33 (0)1 44 71 94 94 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
